INHIBRX BIOSCIENCES, INC. – Trademark Portfolio
Entity Type: 03
INHIBRX BIOSCIENCES, INC. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 4 trademarks are registered and 10 are pending. Notable registered marks include INHIBRX, CONTRA-MAB, and INHIBRX BIOSCIENCES. The owner is based in LA JOLLA, CA.
11025 N. TORREY PINES ROAD, SUITE 140
LA JOLLA, CA 92037
Showing of trademarks Trademarks
Trademark Classifications
INHIBRX BIOSCIENCES, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does INHIBRX BIOSCIENCES, INC. have?
INHIBRX BIOSCIENCES, INC. has 14 U.S. trademarks filed with the USPTO. Of these, 4 registered, 10 pending.
What trademark classes does INHIBRX BIOSCIENCES, INC. file in?
INHIBRX BIOSCIENCES, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are INHIBRX BIOSCIENCES, INC.'s most well-known trademarks?
INHIBRX BIOSCIENCES, INC.'s registered trademark portfolio includes well-known marks such as INHIBRX, CONTRA-MAB, and INHIBRX BIOSCIENCES. These are among 4 currently registered trademarks in the portfolio.
What is INHIBRX BIOSCIENCES, INC.'s trademark registration success rate?
INHIBRX BIOSCIENCES, INC. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 10 applications are pending review.